RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma

NCT01545635 | Terminated Phase 3 DMC

• 1 other identifier: RETIC
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Severe traumatized patients (ISS \> 15) admitted to emergency department (ED) University Hospital Innsbruck with obvious bleeding and/or who are at risk for significant hemorrhage will be screened by rotational thrombelastometry (ROTEM) assays during ED treatment and subsequent surgical/radiological interventions for having coagulopathy (T0). If a patient meets the inclusion criteria (T1) and is recruited for the study, a first study related blood sample (40mL) will be drawn, and data collected. Subsequently, 100 patients will be randomized to receive Fibrinogen concentrate and/or Prothrombin complex concentrate and/or FXIII concentrate for reversal of coagulopathy, while the other 100 patients will receive fresh frozen plasma (FFP),respectively. Treatment failure will be registered if bleeding persists and ROTEM parameters do not improve after two times dosages of study drug. In these cases haemostatic rescue therapy will be administered. CFC (fibrinogen concentrate and/or PCC, and/or FXIII concentrate) will be administered to patients randomized to receive FFP and FFP will be administered to patients of the CFC group. In cases unresponsive to comprehensive treatment or normal ROTEM combined with diffuse bleeding, other haemostatic medications can be administered (e.g rFVIIa, DDAVP, VWF/FVIII concentrate) as judged by the anesthetist in charge. The need and type of any rescue therapy will be documented and a ROTEM will be performed thereafter. At admission to ICU (T0 ICU), 24h (T24 ICU) and 48h(T48 ICU) thereafter further study related blood samples are drawn (40mL each). The indications for transfusion of red blood cells or platelets, administration of antifibrinolytics, treatment of acidosis, hypothermia, hypocalcemia and volume replacement are similar for both groups and treatment is performed according to clinical routine. Besides coagulation management during ED treatment until 24h on ICU, patient's care is not influenced by the study and follows clinical routine.

Conditions

Major Trauma

Keywords

Major trauma; Injury Severity Score; ISS > 15; clinical signs; risk of blood loss; coagulopathy; rotational thrombelastometry; ROTEM

Outcome Measures

Primary Outcomes (1)

• Multiple Organ Failure (MOF)

  Difference in the MOF as assessed by the Sequential Organ Failure Assessment score (SOFA) between treatment groups.

  Variable until 24h on ICU at the end of the IMP-administration

Study Arms (2)

Coagulation factor concentrates

ACTIVE COMPARATOR

Drug: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate

Fresh Frozen Plasma

ACTIVE COMPARATOR

Drug: Fresh Frozen Plasma blood type 0, A, B and AB

Interventions

Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate DRUG

Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10\<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT \>90sec and FIBTEM A10\>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min

Coagulation factor concentrates

Fresh Frozen Plasma blood type 0, A, B and AB DRUG

Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 \<7mm and/or ExTEM CT\>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min

Fresh Frozen Plasma

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female subjects =/\> 18 years and =/\< 80 years
• Major trauma (ISS \> 15)
• Clinical signs of ongoing bleeding or patients who are at risk for significant haemorrhage assessed and judged by the ED team in charge of patient
• Presence of coagulopathy defined by ROTEM assays as follows,
• Patients with concomitant decreased fibrinogen polymerisation (ROTEM® FibTEM A10 of \< 7 mm after 10 min)
• Patients with concomitant decreased coagulation factor levels (ROTEM® ExTEM CT of \> 90 sec)

You may not qualify if:

• Lethal injury
• CPR on the scene,
• Isolated brain injury, burn injury
• Avalanche injury
• Administration of FFP or coagulation factor concentrates before ED admission
• Delayed (\> 6hours after trauma) admittance to ED
• Known use of oral anticoagulants, or platelet aggregation inhibitors within 5 days before injury
• Known history of severe allergic reaction to plasma products
• Known history of congenital hemostasis disturbance, IgA or Protein C deficiency
• Patients with a history of thromboembolic events or heparin induced thrombocytopenia (HIT) type 2 within the last year
• Patients with a body weight \< 45kg and \> 150kg
• Patients that are known to be pregnant
• Jehova's Witness
• Known participation in another clinical trial
• Patient with known refusal of a participation in this clinical trial

Sponsors & Collaborators

• Medical University Innsbruck: lead

Study Sites (1)

Medical University Innsbruck / Department for Anesthesia and Intensive Care Medicine

Innsbruck, Tyrol, 6020, Austria

Location

Related Publications (1)

• Innerhofer P, Fries D, Mittermayr M, Innerhofer N, von Langen D, Hell T, Gruber G, Schmid S, Friesenecker B, Lorenz IH, Strohle M, Rastner V, Trubsbach S, Raab H, Treml B, Wally D, Treichl B, Mayr A, Kranewitter C, Oswald E. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol. 2017 Jun;4(6):e258-e271. doi: 10.1016/S2352-3026(17)30077-7. Epub 2017 Apr 28.

  PMID: 28457980 DERIVED

MeSH Terms

Conditions

Signs and Symptoms; Hemostatic Disorders

Interventions

Fibrinogen; Factor IX

Condition Hierarchy (Ancestors)

Pathological Conditions, Signs and Symptoms; Vascular Diseases; Cardiovascular Diseases; Hemorrhagic Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Acute-Phase Proteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Blood Coagulation Factors; Protein Precursors; Biological Factors; Enzyme Precursors; Enzymes and Coenzymes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: March 1, 2012
• First Posted: March 7, 2012
• Study Start: March 1, 2012
• Primary Completion: February 1, 2016
• Study Completion: February 1, 2016
• Last Updated: March 23, 2016

Record last verified: 2016-03

Locations

AU (1)